REGISTERED
on 09 Aug 2022
Last Applicant/ Owned by
Suite 300E
Washington
DC
20037
Serial Number
88819345 filed on 03rd Mar 2020
Registration Number
6815599 registered on 09th Aug 2022
Filing Basis
1. intent to use
2. use application currently
Disclaimer
NO DATA
HETLIOZ (TASIMELTEON) CAPSULES
Pharmaceutical preparations, containing tasimelteon, for use in the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations, containing tasimelteon, for use in the treatment of sleep disorders
Classification Information
Class [005]
Pharmaceutical Products
Pharmaceutical preparations, containing tasimelteon, for use in the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations, containing tasimelteon, for use in the treatment of sleep disorders
First Use Date in General
01st Dec 2020
First Use Date in Commerce
01st Dec 2020
Mark Details
Serial Number
No 88819345
Mark Type
No Service/Collective Mark
Attorney Docket Number
No VAND-0129US3
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Design Code(s)
26.01.21 -
Circles that are totally or partially shaded
26.01.31 -
Five or more circles
Legal History
| Status Date | Action Taken |
|---|---|
| 09th Aug 2022 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| 09th Aug 2022 | REGISTERED-PRINCIPAL REGISTER |
| 07th Jul 2022 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| 06th Jul 2022 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| 09th Jun 2022 | ASSIGNED TO EXAMINER |
| 21st Apr 2022 | STATEMENT OF USE PROCESSING COMPLETE |
| 21st Apr 2022 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 11th Apr 2022 | USE AMENDMENT FILED |
| 11th Apr 2022 | TEAS STATEMENT OF USE RECEIVED |
| 12th Oct 2021 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |